Comparing Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)Defense World · Oct 5, 2026
Critical Analysis: Molecular Partners (NASDAQ:MOLN) vs. Vertex Pharmaceuticals (NASDAQ:VRTX)Defense World · Sep 21, 2026
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a StudyGlobeNewsWire · Aug 25, 2026Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 25, 2026 | -$0.45 | -$0.44 | Beat |
| May 12, 2026 | -$0.38 | -$0.45 | Miss |
| Mar 12, 2026 | -$0.40 | -$0.41 | Miss |
| Oct 30, 2025 | -$0.46 | -$0.41 | Beat |
| Aug 25, 2025 | -$0.53 | -$0.67 | Miss |
| May 15, 2025 | -$0.42 | -$0.50 | Miss |